Highlighting Immunotherapy Progress in Bladder Cancer
Shilpa Gupta, MD, discusses the progress over the last few years in bladder cancer.
Shilpa Gupta, MD, genitourinary oncologist at the University of Minnesota, discusses the progress made with immunotherapy in bladder cancer over the last few years.
There has been many advances in terms of immunotherapy in this patient population, and many trials are combining chemotherapy with these agents in the hopes of improving overall survival and gaining more durable responses, says Gupta. Later this year, we will learn more about these data as they read out.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
